Clinical Trial

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

Study acronym: EASE SBS 2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 30, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS). Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.
Protocol Amendment History 20 amendments
This ClinicalTrials.gov record has been amended 20 times since 2019-04-03; most recent amendment 2026-01-29.
Status change: Recruiting → Active, Not Recruiting 2024-09-16
Status change: Not Yet Recruiting → Recruiting 2019-05-08
Trial Details
NCT Number NCT03905707
Lead Sponsor Zealand Pharma
Conditions Short Bowel Syndrome
Enrollment 145 participants
Start Date 2019-05-07
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2026-01-30